The 10 most recent market catalysts affecting $BLCO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 75
Bausch + Lomb Receives FDA Warning Letter Over Sterile Drug Manufacturing At Tampa Plant, Citing Inadequate Aseptic Controls And Persistent Microbial Contamination; Products Deemed Adulterated
Bausch + Lomb received a Warning Letter from the FDA for its Tampa, Florida sterile drug manufacturing facility, citing significant violations including inadequate aseptic controls…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
Leerink Partners Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $24
Leerink Partners, through analyst Daniel Clark, has initiated coverage on Bausch & Lomb (BLCO) with an 'Outperform' rating and a $24 price target. This event is significant because…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential
Bausch + Lomb announced the progression of two key ophthalmic therapies into advanced clinical testing. The dry eye combination therapy, despite missing its Day 29 primary endpoint…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 85
Bausch + Lomb Says Dual-Action Dry Eye Drop Missed Phase 2 Primary Endpoint At Day 29, Met Secondary Endpoint At Day 15; Advancing To Phase 3 With Day 15 Primary Endpoint
The headline signals a significant event for Bausch + Lomb (BLCO) as its dry eye drug, a potential blockbuster, experienced a mixed Phase 2 outcome. Missing the Day 29 primary endp…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Raises Price Target to $21
HC Wainwright & Co. analyst Yi Chen maintained a 'Buy' rating on Bausch & Lomb (BLCO) and raised the price target from $20 to $21. This action indicates a continued bullish outlook…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Bausch & Lomb, Raises Price Target to $23
UBS analyst Patrick Wood maintained a 'Buy' rating on Bausch & Lomb and raised the price target from $21 to $23. This action signals continued confidence in the company's future pe…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 92
Bausch & Lomb Q2 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $1.394B Beat $1.369B Estimate
Bausch & Lomb (BLCO) announced Q2 adjusted EPS of $0.16, beating the $0.15 consensus by 6.67%, and sales of $1.394 billion, surpassing the $1.369 billion estimate by 1.84%. This st…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
Bausch & Lomb Raises FY2026 Sales Guidance from $5.420B-$5.520B to $5.440B-$5.540B vs $5.468B Est
Bausch & Lomb (BLCO) has updated its fiscal year 2026 sales guidance, raising the lower and upper bounds by $20 million each. This revision moves the new range to $5.440 billion-$5…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
Bausch & Lomb Q2 Adj. EPS $0.16, Inline, Sales $1.394B Beat $1.368B Estimate
Bausch & Lomb's Q2 results show a positive trend with sales beating estimates and a substantial year-over-year increase in both EPS and sales. This indicates healthy demand for the…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 65
UBS Initiates Coverage On Bausch & Lomb with Buy Rating, Announces Price Target of $21
UBS analyst Patrick Wood initiated coverage on Bausch & Lomb (BLCO) with a 'Buy' rating and a $21 price target. This is a positive development for BLCO as new analyst coverage, esp…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.